What ChondroFiller injection offers shoulder cartilage patients

ChondroFiller® is an injectable collagen scaffold delivered under real-time ultrasound guidance as an outpatient clinic appointment — it is not a surgical procedure and involves no incision, no general anaesthetic, and no theatre admission. The product is a CE-marked Class III medical device composed of acellular, murine-derived Type I collagen that gels in situ within minutes of injection, providing a structural matrix that recruits the patient's own cells to promote endogenous cartilage repair.

The glenohumeral joint — the principal site affected in focal shoulder cartilage injuries, particularly those related to sport — is an explicitly listed indication for ChondroFiller®, alongside the knee, hip, ankle, elbow, and wrist. A typical treatment visit takes approximately one hour and covers imaging review, defect mapping, the ultrasound-guided injection itself, intravenous antibiotic cover, and arrangement of a follow-up appointment at six weeks.

Access is through self-funded private care only. ChondroFiller® is not available via the NHS and is not covered by standard private medical insurance, which is a practical consideration for most patients at the outset.

How the scaffold works inside the joint

The mechanism proceeds in four stages once the material enters the joint. The collagen scaffold — acellular, meaning it contains no living cells from a donor — flows into the focal defect and conforms to its shape. Within minutes of injection, it self-gels, forming a stable, three-dimensional matrix that sits directly within the lesion rather than dispersing through the surrounding joint fluid.

That gelled scaffold then acts as a chemotactic matrix, sending biochemical signals that draw the patient's own progenitor cells inward from the adjacent synovium and subchondral bone. These recruited cells gradually settle into the framework, mature into chondrocytes, and begin depositing a hyaline-like cartilage matrix. The repair process is driven entirely by the patient's own biology — not by donor cells or synthetic growth factors. As the new tissue develops and consolidates, the collagen scaffold gradually resorbs, leaving the repair tissue rather than a permanent foreign material behind.

Accurate placement is particularly important in the glenohumeral joint, where the curved articular geometry makes precise targeting difficult. Real-time ultrasound imaging allows the clinician to confirm needle position within the defect before delivery — a level of intra-procedural precision that cannot be reliably achieved by surface landmark alone in a joint seated this deeply.

Which shoulder patients are typically assessed

Suitability for ChondroFiller® injection rests on a specific pattern of damage rather than on age or general joint wear. The treatment is designed for isolated, focal cartilage lesions — Grade III or IV on standard grading scales — where the cartilage within the defect has deteriorated but the surrounding borders remain structurally intact. Patients presenting with diffuse osteoarthritis, where loss is widespread across the joint surface, are not typically suitable candidates for this pathway.

In the shoulder, sports-related trauma to the glenohumeral joint is the most common clinical context in which an assessment is sought. A focal impact injury or chronic overload lesion in an otherwise structurally sound joint is the setting in which the scaffold has most to offer.

MRI is the diagnostic gatekeeper. Before any treatment plan is finalised, imaging is reviewed to confirm defect grade, location, and the quality of the cartilage rim surrounding the lesion. That assessment also determines defect area: the injectable pathway can accommodate lesions up to 6 cm², covering a broad range of focal injuries. Defect mapping from MRI forms part of the pre-injection consultation, and a written treatment plan is agreed before any injection proceeds.

One practical distinction from some surgical regenerative approaches: the injectable route imposes no upper age limit. Eligibility is assessed on the anatomy of the defect rather than on a chronological threshold, as the scaffold recruits the patient's own progenitor cells regardless of age.

What the outcome evidence shows — and where gaps remain

Available outcome data for the shoulder sit at two levels of certainty, and it is worth being clear about that distinction from the outset.

In early observational data from upper-limb cases, patients assessed after ChondroFiller® injection reported marked reductions in pain on the Numeric Rating Scale (NRS) and significant functional improvements on the Disability of the Arm, Shoulder and Hand (DASH) questionnaire. Grip and pincer strength — measured via Jamar dynamometry and pinch testing — also increased. Post-injection MRI in the same cohort showed structural changes consistent with early repair: reduced bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space. These signals point in a consistent direction, but they derive from observational data rather than controlled trials; shoulder-specific randomised controlled evidence has not yet been published.

The most detailed structural and functional data currently come from four European knee studies. Across those cohorts, IKDC scores improved by approximately 30 points (mean 32.4 in the Jerosch post-market clinical follow-up study at three years) — well above the established 16.7-point minimum clinically important difference. MOCART structural scores ranged from 81.6 to 84.3, reflecting more than 80% defect filling with good integration into surrounding native cartilage. The mechanism of acellular matrix-induced chondrogenesis is the same regardless of joint, which is why these figures are the best available structural proxy for the shoulder — but the extrapolation is explicit, not assumed.

On safety, the manufacturer's Clinical Evaluation Report (CER v.09, April 2025) records a complication rate of approximately 0% and a reoperation rate of 3–8% — comparing favourably with microfracture (reoperation up to 41%) and ACI/MACI (complication rate up to 17%; reoperation up to 37%). A specialist assessment remains the appropriate step for understanding what the evidence means for any individual's anatomy.

What to expect at the appointment

On arrival, the treating clinician reviews the MRI, confirms the defect map, and signs off the treatment plan before any injection proceeds. Ultrasound then guides probe placement over the glenohumeral joint; after local anaesthetic is applied, the collagen scaffold is delivered by needle under continuous real-time imaging. A short observation period follows before discharge — the full sequence fits within a single outpatient appointment.

The standard package covers the consultation, ultrasound imaging, the ChondroFiller® product, the injection, intravenous antibiotic cover, and a 6-week follow-up. IV antibiotic prophylaxis is routine protocol for any intra-articular injection — standard practice to minimise infection risk whenever a needle enters a joint cavity, not a marker of surgical complexity.

For patients presenting with a focal cartilage defect alongside synovial pain, a separate injectable option — Arthrosamid®, a hydrogel that integrates into the synovial lining — can be delivered in the same session. The two products work through entirely different mechanisms: ChondroFiller® is a regenerative scaffold that recruits the patient's own progenitor cells within the cartilage defect, while Arthrosamid® is a non-regenerative hydrogel acting on the joint lining. They are not interchangeable and should not be described as the same treatment.

International patients can consolidate the imaging review, consultation, and injection into one visit. Post-injection guidance on activity — including any joint-specific restrictions in the days and weeks that follow — is provided at discharge and revisited at the 6-week follow-up.

Cost, access, and finding a specialist

Guide costs start at £3,000 for a single-box treatment and scale to approximately £8,000 depending on the number of boxes required for the defect area. That figure covers consultation, ultrasound imaging, the ChondroFiller® product, the injection itself, intravenous antibiotic cover, and the 6-week follow-up appointment. Because pricing varies by clinical presentation and defect size, patients should confirm current costs directly with the treating clinic.

ChondroFiller® injection sits outside NHS commissioning pathways and is not reimbursable through standard private medical insurance, so treatment is arranged on a self-funded basis.

The Search MSK specialist directory lists clinicians across the UK who offer ChondroFiller® injection for focal cartilage defects — patients can filter by region and specialty to find a suitable practitioner near them.

Questions worth raising at your first consultation

• Does my MRI confirm the defect grade, size, and border quality needed for the injectable pathway?
• Given my defect characteristics, is the injectable approach or the surgical scaffold route more appropriate for me?
• What follow-up imaging is included, and at what point after injection would structural repair be assessable on MRI?